• NBIX

Neurocrine Biosciences rises on FDA nod for CAH drug

Neurocrine Biosciences' shares rose 5.7% after FDA approved CRENESSITY for congenital adrenal hyperplasia, marking a significant advancement in treatment options for affected patients.